Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
2008 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
Sachse-Seeboth, C.; Pfeil, J.; Sehrt, D.; Meineke, I.; Tzvetkov, M.; Bruns, E. & Poser, W. et al. (2008)
Clinical Pharmacology & Therapeutics, 85(3) pp. 273-276. DOI: https://doi.org/10.1038/clpt.2008.213
Documents & Media
closedAccess1.2 MBAdobe PDF
Details
- Authors
- Sachse-Seeboth, C.; Pfeil, J.; Sehrt, D.; Meineke, I.; Tzvetkov, M.; Bruns, E.; Poser, W.; Vormfelde, S. V.; Brockmöller, J.
- Abstract
- The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9 2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9 3/ 3 homozygotes than in CYP2C9 1/ 1 homozygotes. CYP2C9 3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9 3 variant may influence both the therapeutic and adverse effects of THC.
- Issue Date
- 2008
- Journal
- Clinical Pharmacology & Therapeutics
- Language
- English
